Kamlesh Khunti/X
Aug 8, 2025, 13:26
Kamlesh Khunti: GLP-1 and SGLT2 in T2D – Discontinuation, Reinitiation and Switching Swedish registry data
Kamlesh Khunti, Professor of Primary Care Diabetes and Vascular Medicine, GP, University of Leicester, shared a post on X:
“GLP-1 and SGLT2 in T2D: Discontinuation, Reinitiation and Switching Swedish registry data
Discontinuation
GLP-1 RA: 24% at 1 yr, 39% at 3 yrs
SGLT2i: 28% at 1 yr, 46% at 3 yrs
Despite high discontinuation, 70–80% remained on therapy long term.”
Title: Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes
Authors: Carl-Emil Lim, Björn Pasternak, Björn Eliasson, Peter Ueda
More posts featuring GLP-1 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54
Aug 8, 2025, 15:49